MURRAY, Utah, Feb. 27, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM) ("R1" or the "Company"), a leading provider of technology-driven solutions that transform the financial performance and patient experience for health systems, hospitals, and physician groups, today announced results for the three months and year ended December 31, 2023.
Fourth Quarter 2023 Results:
Full Year 2023 Results:
“R1 executed on its key objectives in 2023. We established a stronger foundation for growth, stabilized key metrics for several clients and delivered approximately $30 million in synergies from the Cloudmed integration,” stated Lee Rivas, R1's CEO. “In addition, we strengthened our technology platform by driving innovation through generative AI and enhanced our global infrastructure to improve our performance and competitive position in the market.”
Mr. Rivas added, “We enter 2024 with a more diversified business, enhanced technology initiatives and increased global scale. Our strategy is to leverage our best-in-class capabilities to deploy flexible models that meet customers where they are in their revenue cycle journey. We believe R1’s breadth of capabilities and data-driven technology platform, combined with our focus on operational excellence, positions us to drive value for our customers while delivering long-term sustainable growth and improved financial performance for our shareholders.”
2024 Outlook
For 2024, R1 expects to generate:
Jennifer Williams, R1’s CFO said, “Our outlook for fiscal 2024 reflects the strength of our platform and our focus on both growth and operating discipline to deliver great value for our customers and shareholders. To further our leadership position in the industry, we will continue improving execution across our business, advancing our new business pipeline and investing in technology, while remaining committed to improving margins and cash flows.”
Supplemental Forward-Looking Information and Assumptions for Fiscal Year 2024
The Company is providing the following supplemental expectations and related assumptions regarding its fiscal year 2024 results, all of which are subject to change, to further provide transparency to investors:
Conference Call and Webcast Details
R1’s management team will host a conference call today at 8:00 a.m. Eastern Time to discuss its financial results and business outlook. To participate, please dial 888-330-2022 (646-960-0690 outside the U.S. and Canada) using conference code number 5681952. A live webcast and replay of the call will be available at the Investor Relations section of the Company’s website at ir.r1rcm.com.
Non-GAAP Financial Measures
In order to provide a more comprehensive understanding of the information used by R1’s management team in financial and operational decision making, the Company supplements its GAAP consolidated financial statements with certain non-GAAP financial measures, including adjusted EBITDA, non-GAAP cost of services, non-GAAP selling, general and administrative expenses, and net debt. Adjusted EBITDA is defined as GAAP net income (loss) before net interest income/expense, income tax provision/benefit, depreciation and amortization expense, share-based compensation expense, CoyCo 2, L.P. (“CoyCo 2”) share-based compensation expense, and certain other items, including business acquisition costs, integration costs, technology transformation, strategic initiatives, and facility-exit charges. Non-GAAP cost of services is defined as GAAP cost of services less share-based compensation expense, CoyCo 2 share-based compensation expense, and depreciation and amortization expense attributed to cost of services. Non-GAAP selling, general and administrative expenses is defined as GAAP selling, general and administrative expenses less share-based compensation expense, CoyCo 2 share-based compensation expense, and depreciation and amortization expense attributed to selling, general and administrative expenses. Net debt is defined as debt less cash and cash equivalents, inclusive of restricted cash. Adjusted EBITDA guidance is reconciled to operating income guidance, the most closely comparable available GAAP measure.
The Company's board of directors and management team use adjusted EBITDA as (i) one of the primary methods for planning and forecasting overall expectations and for evaluating actual results against such expectations and (ii) a performance evaluation metric in determining achievement of certain executive incentive compensation programs, as well as for incentive compensation programs for employees. Non-GAAP cost of services and non-GAAP selling, general and administrative expenses are used to calculate adjusted EBITDA. Net debt is used as a supplemental measure of the Company's liquidity.
Tables 4 through 9 present a reconciliation of GAAP financial measures to non-GAAP financial measures. Non-GAAP measures should be considered in addition to, but not as a substitute for, the information prepared in accordance with GAAP.
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, included in this press release are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “designed,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “outlook,” “plan,” “predict,” “project,” “see,” “seek,” “target,” “would” and similar expressions or variations or negatives of these words are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such forward-looking statements include, among other things, statements about the Company’s strategy, future operations, future financial position, prospects, plans, objectives of management, ability to successfully deliver on commitments to customers, ability to deploy new business as planned, ability to successfully implement new technologies, and expected market growth. Such forward-looking statements are based on management’s current expectations about future events as of the date hereof and involve many risks and uncertainties that could cause the Company’s actual results to differ materially from those expressed or implied in its forward-looking statements. Subsequent events and developments, including actual results or changes in the Company’s assumptions, may cause the Company’s views to change. The Company does not undertake to update its forward-looking statements except to the extent required by applicable law. Readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements included herein are expressly qualified in their entirety by these cautionary statements. The Company’s actual results and outcomes could differ materially from those included in these forward-looking statements as a result of various factors, including, but not limited to, economic downturns and market conditions beyond the Company’s control, including high inflation; the quality of global financial markets; the Company’s ability to timely and successfully achieve the anticipated benefits and potential synergies of the acquisitions of Cloudmed and Acclara; the Company’s ability to retain existing customers or acquire new customers; the development of markets for the Company’s revenue cycle management offering; variability in the lead time of prospective customers; competition within the market; breaches or failures of the Company’s information security measures or unauthorized access to a customer’s data; delayed or unsuccessful implementation of the Company’s technologies or services, or unexpected implementation costs; disruptions in or damages to the Company’s global business services centers and third-party operated data centers; the volatility of the Company’s stock price; the impact of the recent restatements of the financial statements for the applicable periods on the price of the Company’s common stock, reputation and relationships with its investors, suppliers, customers, employees and other parties; the Company’s substantial indebtedness; and the factors set forth under the heading “Risk Factors” in the Company’s most recent annual report on Form 10-K, and any other periodic reports that the Company may file with the U.S. Securities and Exchange Commission.
About R1 RCM
R1 is a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers. R1’s proven and scalable operating models seamlessly complement a healthcare organization’s infrastructure, quickly driving sustainable improvements to net patient revenue and cash flows while reducing operating costs and enhancing the patient experience. To learn more, visit: r1rcm.com.
Contact:
R1 RCM Inc.
Investor Relations:
Evan Smith, CFA
516-743-5184
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Relations:
Yancey Casey
Amendola Communications
678-895-9401
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Table 1 | ||||||||
| R1 RCM Inc. | ||||||||
| Consolidated Balance Sheets | ||||||||
| (In millions) | ||||||||
| (Unaudited) | ||||||||
| December 31, | ||||||||
| 2023 | 2022 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 173.6 | $ | 110.1 | ||||
| Accounts receivable, net of $48.2 million and $15.1 million allowance as of December 31, 2023 and 2022, respectively | 243.3 | 235.2 | ||||||
| Accounts receivable - related party, net of $0.1 million allowance as of December 31, 2023 and 2022 | 26.1 | 25.0 | ||||||
| Current portion of contract assets, net | 94.4 | 83.9 | ||||||
| Prepaid expenses and other current assets | 95.9 | 110.3 | ||||||
| Total current assets | 633.3 | 564.5 | ||||||
| Property, equipment and software, net | 173.7 | 164.8 | ||||||
| Operating lease right-of-use assets | 62.5 | 80.5 | ||||||
| Non-current portion of contract assets, net | 37.7 | 32.0 | ||||||
| Non-current portion of deferred contract costs | 30.4 | 26.7 | ||||||
| Intangible assets, net | 1,310.7 | 1,514.5 | ||||||
| Goodwill | 2,629.4 | 2,640.3 | ||||||
| Non-current deferred tax assets | 10.9 | 10.4 | ||||||
| Other assets | 71.6 | 88.1 | ||||||
| Total assets | $ | 4,960.2 | $ | 5,121.8 | ||||
| Liabilities | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 22.7 | $ | 33.4 | ||||
| Current portion of customer liabilities | 39.8 | 57.5 | ||||||
| Current portion of customer liabilities - related party | 5.2 | 7.4 | ||||||
| Accrued compensation and benefits | 126.3 | 109.0 | ||||||
| Current portion of operating lease liabilities | 19.3 | 18.0 | ||||||
| Current portion of long-term debt | 67.0 | 53.9 | ||||||
| Accrued expenses and other current liabilities | 65.9 | 70.5 | ||||||
| Total current liabilities | 346.2 | 349.7 | ||||||
| Non-current portion of customer liabilities | 2.7 | 5.0 | ||||||
| Non-current portion of customer liabilities - related party | 11.8 | 13.7 | ||||||
| Non-current portion of operating lease liabilities | 77.8 | 94.4 | ||||||
| Long-term debt | 1,570.5 | 1,732.6 | ||||||
| Non-current deferred tax liabilities | 176.6 | 200.8 | ||||||
| Other non-current liabilities | 23.2 | 23.1 | ||||||
| Total liabilities | 2,208.8 | 2,419.3 | ||||||
| Stockholders’ equity: | ||||||||
| Common stock | 4.5 | 4.4 | ||||||
| Additional paid-in capital | 3,197.4 | 3,123.3 | ||||||
| Accumulated deficit | (136.7 | ) | (140.0 | ) | ||||
| Accumulated other comprehensive loss | (5.9 | ) | (3.4 | ) | ||||
| Treasury stock | (307.9 | ) | (281.8 | ) | ||||
| Total stockholders’ equity | 2,751.4 | 2,702.5 | ||||||
| Total liabilities and stockholders’ equity | $ | 4,960.2 | $ | 5,121.8 | ||||
| Table 2 | ||||||||||||||
| R1 RCM Inc. | ||||||||||||||
| Consolidated Statements of Operations | ||||||||||||||
| (In millions, except share and per share data) | ||||||||||||||
| (Unaudited) | (Unaudited) | (Unaudited) | ||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | |||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||
| Net operating fees | $ | 369.1 | $ | 344.9 | $ | 1,455.9 | $ | 1,309.7 | ||||||
| Incentive fees | 23.9 | 25.9 | 108.4 | 106.8 | ||||||||||
| Modular and other | 182.1 | 162.5 | 689.9 | 389.9 | ||||||||||
| Net services revenue | 575.1 | 533.3 | 2,254.2 | 1,806.4 | ||||||||||
| Operating expenses: | ||||||||||||||
| Cost of services | 441.6 | 435.5 | 1,769.7 | 1,446.9 | ||||||||||
| Selling, general and administrative | 55.7 | 54.3 | 220.0 | 172.5 | ||||||||||
| Other expenses | 28.7 | 47.3 | 116.6 | 189.8 | ||||||||||
| Total operating expenses | 526.0 | 537.1 | 2,106.3 | 1,809.2 | ||||||||||
| Income (loss) from operations | 49.1 | (3.8 | ) | 147.9 | (2.8 | ) | ||||||||
| Net interest expense | 31.6 | 28.7 | 126.9 | 64.0 | ||||||||||
| Income (loss) before income tax provision (benefit) | 17.5 | (32.5 | ) | 21.0 | (66.8 | ) | ||||||||
| Income tax provision (benefit) | 16.1 | 4.1 | 17.7 | (3.5 | ) | |||||||||
| Net income (loss) | $ | 1.4 | $ | (36.6 | ) | $ | 3.3 | $ | (63.3 | ) | ||||
| Net income (loss) per common share: | ||||||||||||||
| Basic | $ | — | $ | (0.09 | ) | $ | 0.01 | $ | (0.18 | ) | ||||
| Diluted | $ | — | $ | (0.09 | ) | $ | 0.01 | $ | (0.18 | ) | ||||
| Weighted average shares used in calculating net income (loss) per common share: | ||||||||||||||
| Basic | 419,440,458 | 416,680,429 | 418,587,390 | 352,337,767 | ||||||||||
| Diluted | 451,499,913 | 416,680,429 | 454,094,374 | 352,337,767 | ||||||||||
| Table 3 | ||||||||
| R1 RCM Inc. | ||||||||
| Consolidated Statements of Cash Flows | ||||||||
| (In millions) | ||||||||
| (Unaudited) | ||||||||
| Year Ended December 31, | ||||||||
| 2023 | 2022 | |||||||
| Operating activities | ||||||||
| Net income (loss) | $ | 3.3 | $ | (63.3 | ) | |||
| Adjustments to reconcile net income (loss) to net cash provided by (used in) operations: | ||||||||
| Depreciation and amortization | 278.3 | 172.0 | ||||||
| Amortization of debt issuance costs | 5.7 | 3.6 | ||||||
| Share-based compensation | 64.2 | 59.8 | ||||||
| CoyCo 2 share-based compensation | 7.3 | 5.1 | ||||||
| Loss/(gain) on disposal and right-of-use asset write-downs | 10.0 | 21.1 | ||||||
| Provision for credit losses | 34.6 | 11.8 | ||||||
| Deferred income taxes | (14.6 | ) | (6.8 | ) | ||||
| Non-cash lease expense | 11.5 | 14.0 | ||||||
| Other | 12.3 | 6.5 | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable and related party accounts receivable | (44.0 | ) | (51.8 | ) | ||||
| Contract assets | (15.2 | ) | (24.1 | ) | ||||
| Prepaid expenses and other assets | 3.9 | (40.5 | ) | |||||
| Accounts payable | (10.9 | ) | (16.0 | ) | ||||
| Accrued compensation and benefits | 17.4 | (69.5 | ) | |||||
| Operating lease liabilities | (18.0 | ) | (18.9 | ) | ||||
| Other liabilities | 17.9 | (1.7 | ) | |||||
| Customer liabilities and customer liabilities - related party | (23.6 | ) | (11.2 | ) | ||||
| Net cash provided by (used in) operating activities | 340.1 | (9.9 | ) | |||||
| Investing activities | ||||||||
| Purchases of property, equipment, and software | (102.5 | ) | (93.5 | ) | ||||
| Payment for business acquisitions, net of cash acquired | — | (847.7 | ) | |||||
| Other | (0.3 | ) | (8.3 | ) | ||||
| Net cash used in investing activities | (102.8 | ) | (949.5 | ) | ||||
| Financing activities | ||||||||
| Issuance of senior secured debt, net of discount and issuance costs | — | 1,016.6 | ||||||
| Borrowings on revolver | 30.0 | 50.0 | ||||||
| Payment of debt issuance costs | — | (1.0 | ) | |||||
| Repayment of senior secured debt | (53.9 | ) | (25.5 | ) | ||||
| Repayments on revolver | (130.0 | ) | (30.0 | ) | ||||
| Payment of equity issuance costs | — | (2.0 | ) | |||||
| Exercise of vested stock options | 1.3 | 4.6 | ||||||
| Purchase of treasury stock | — | (39.3 | ) | |||||
| Shares withheld for taxes | (26.5 | ) | (30.2 | ) | ||||
| Other | 5.2 | (0.2 | ) | |||||
| Net cash (used in) provided by financing activities | (173.9 | ) | 943.0 | |||||
| Effect of exchange rate changes in cash | 0.1 | (3.6 | ) | |||||
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 63.5 | (20.0 | ) | |||||
| Cash, cash equivalents, and restricted cash at beginning of period | 110.1 | 130.1 | ||||||
| Cash, cash equivalents, and restricted cash at end of period | $ | 173.6 | $ | 110.1 | ||||
| Table 4 | ||||||||||||||||||||||||||||
| R1 RCM Inc. | ||||||||||||||||||||||||||||
| Reconciliation of GAAP Net Income (Loss) to Non-GAAP Adjusted EBITDA (Unaudited) | ||||||||||||||||||||||||||||
| (In millions) | ||||||||||||||||||||||||||||
| Three Months Ended December 31, | 2023 vs. 2022 Change | Year Ended December 31, | 2023 vs. 2022 Change | |||||||||||||||||||||||||
| 2023 | 2022 | Amount | % | 2023 | 2022 | Amount | % | |||||||||||||||||||||
| Net income (loss) | $ | 1.4 | $ | (36.6 | ) | $ | 38.0 | (104 | )% | $ | 3.3 | $ | (63.3 | ) | $ | 66.6 | (105 | )% | ||||||||||
| Net interest expense | 31.6 | 28.7 | 2.9 | 10 | % | 126.9 | 64.0 | 62.9 | 98 | % | ||||||||||||||||||
| Income tax provision (benefit) | 16.1 | 4.1 | 12.0 | (293 | )% | 17.7 | (3.5 | ) | 21.2 | (606 | )% | |||||||||||||||||
| Depreciation and amortization expense | 72.7 | 64.2 | 8.5 | 13 | % | 278.3 | 172.0 | 106.3 | 62 | % | ||||||||||||||||||
| Share-based compensation expense | 15.3 | 15.8 | (0.5 | ) | (3 | )% | 64.2 | 59.7 | 4.5 | 8 | % | |||||||||||||||||
| CoyCo 2 share-based compensation expense | 1.9 | 2.1 | (0.2 | ) | — | % | 7.3 | 5.1 | 2.2 | — | % | |||||||||||||||||
| Other expenses (1) | 28.7 | 47.3 | (18.6 | ) | (39 | )% | 116.6 | 189.8 | (73.2 | ) | (39 | )% | ||||||||||||||||
| Adjusted EBITDA (non-GAAP) | $ | 167.7 | $ | 125.6 | $ | 42.1 | 34 | % | $ | 614.3 | $ | 423.8 | $ | 190.5 | 45 | % | ||||||||||||
(1) For details see Note 14, Other Expenses, to the Consolidated Financial Statements included in the Company's Annual Report on Form 10-K.
| Table 5 | |||||||||||||
| R1 RCM Inc. | |||||||||||||
| Reconciliation of GAAP Cost of Services to Non-GAAP Cost of Services (Unaudited) | |||||||||||||
| (In millions) | |||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||
| Cost of services | $ | 441.6 | $ | 435.5 | $ | 1,769.7 | $ | 1,446.9 | |||||
| Less: | |||||||||||||
| Share-based compensation expense | 10.9 | 7.4 | 41.6 | 28.1 | |||||||||
| CoyCo 2 share-based compensation expense | 0.4 | (0.3 | ) | 1.8 | 0.7 | ||||||||
| Depreciation and amortization expense | 72.5 | 63.8 | 277.1 | 170.8 | |||||||||
| Non-GAAP cost of services | $ | 357.8 | $ | 364.6 | $ | 1,449.2 | $ | 1,247.3 | |||||
| Table 6 | ||||||||||||
| R1 RCM Inc. | ||||||||||||
| Reconciliation of GAAP Selling, General and Administrative to Non-GAAP Selling, General and Administrative (Unaudited) | ||||||||||||
| (In millions) | ||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | |||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||
| Selling, general and administrative | $ | 55.7 | $ | 54.3 | $ | 220.0 | $ | 172.5 | ||||
| Less: | ||||||||||||
| Share-based compensation expense | 4.4 | 8.4 | 22.6 | 31.6 | ||||||||
| CoyCo 2 share-based compensation expense | 1.5 | 2.4 | 5.5 | 4.4 | ||||||||
| Depreciation and amortization expense | 0.2 | 0.4 | 1.2 | 1.2 | ||||||||
| Non-GAAP selling, general and administrative | $ | 49.6 | $ | 43.1 | $ | 190.7 | $ | 135.3 | ||||
| Table 7 | ||||||||||||
| R1 RCM Inc. | ||||||||||||
| Consolidated Non-GAAP Financial Information (Unaudited) | ||||||||||||
| (In millions) | ||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | |||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||
| Net operating fees | $ | 369.1 | $ | 344.9 | $ | 1,455.9 | $ | 1,309.7 | ||||
| Incentive fees | 23.9 | 25.9 | 108.4 | 106.8 | ||||||||
| Modular and other | 182.1 | 162.5 | 689.9 | 389.9 | ||||||||
| Net services revenue | 575.1 | 533.3 | 2,254.2 | 1,806.4 | ||||||||
| Operating expenses: | ||||||||||||
| Cost of services (non-GAAP) | 357.8 | 364.6 | 1,449.2 | 1,247.3 | ||||||||
| Selling, general and administrative (non-GAAP) | 49.6 | 43.1 | 190.7 | 135.3 | ||||||||
| Sub-total (non-GAAP) | 407.4 | 407.7 | 1,639.9 | 1,382.6 | ||||||||
| Adjusted EBITDA | $ | 167.7 | $ | 125.6 | $ | 614.3 | $ | 423.8 | ||||
| Table 8 | |
| R1 RCM Inc. | |
| Reconciliation of GAAP Operating Income Guidance to Non-GAAP Adjusted EBITDA Guidance (Unaudited) | |
| (In millions) | |
| 2024E | |
| GAAP Operating Income Guidance | $105-135 |
| Plus: | |
| Depreciation and amortization expense | $330-350 |
| Share-based compensation expense | $80-90 |
| Strategic initiatives, severance and other costs | $105-125 |
| Adjusted EBITDA Guidance | $650-670 |
| Table 9 | |||||
| R1 RCM Inc. | |||||
| Reconciliation of Total Debt to Net Debt (Unaudited) | |||||
| (In millions) | |||||
| December 31, | December 31, | ||||
| 2023 | 2022 | ||||
| Senior Revolver | $ | — | $ | 100.0 | |
| Term A Loans | 1,162.5 | 1,211.4 | |||
| Term B Loan | 493.8 | 498.7 | |||
| Total debt | 1,656.3 | 1,810.1 | |||
| Less: | |||||
| Cash and cash equivalents | 173.6 | 110.1 | |||
| Net Debt | $ | 1,482.7 | $ | 1,700.0 | |
| Last Trade: | US$14.31 |
| Daily Volume: | 0 |
| Market Cap: | US$6.040B |
November 05, 2024 August 07, 2024 August 01, 2024 June 17, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
